NCCN now lists the brain-penetrant ROS1 inhibitor after progression on earlier TKIs, including as a preferred option for ...

Data presented at ESMO Congress 2026 show lifileucel met its feasibility end point in refractory sarcoma, with 80% disease ...

Fewer than two-thirds of patients prescribed augmentation begin infusions, and half of starters miss doses. Structured ...

UAB experts said new bladder cancer, myeloma, and lung cancer therapies are changing care, but access and costs remain barriers.

Curran urges clinicians to treat ALL treatment guidance as a baseline and, when resources are limited, to focus on what ...

Two pivotal trials, built on different designs and chemotherapy backbones, delivered comparable, if modest, survival gains in ...

Three experts apply policy, pharmacy operations, and member-level lenses to the same prescriptions to show why cost at the ...

Katelyn B. Meyer, PharmD, discusses how payers can prepare for emerging specialty therapies, from cell and gene therapies to ...

Approximately 4.3 million Medicare beneficiaries will have their plans terminated at the end of 2026—including 3.1 million ...

Most Medicaid enrollees who lost coverage during the unwinding were removed for procedural reasons, and expansion adults will ...

Among patients with essential thrombocythemia, higher average ropeginterferon alfa-2b exposure was associated with greater JAK2V617F allele burden reduction at 6 or 7 months (P = .021).

Among youths who misused each drug class, those with depression were more likely to cite helping with feelings and emotions as their main reason for misusing opioid analgesics (10.2% vs 3.7%; P = .01) ...